ocomotion after stroke - LokS

niklinik Köln0 sites90 target enrollmentMay 9, 2022

ConditionsI63.9 Cerebral infarction, unspecified

Overview

Phase: 未知
Intervention: Not specified
Conditions: I63.9
Sponsor: niklinik Köln
Enrollment: 90
Status: Not yet recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

May 9, 2022

End Date

TBD

Last Updated

last year

Study Type

Interventional

Sex

All

Investigators

Sponsor

niklinik Köln

Eligibility Criteria

Inclusion Criteria

•written consent, ischaemic stroke, hemiparesis with impaired unilateral leg\-motor function

Exclusion Criteria

•Subjects who are legally detained in an official institute (§20 MPG), participation in a clinical trial within the last 12 weeks, electronic implants or ferromagnetic implants located in the head, neck or thorax (eg, clips, intracranial shunt, artificial heart valve, pacemaker), medication pump (eg, insulin pump), metal splinters in eye or head, pregnancy/breastfeeding, severe neurodegenerative disease, severe neuroinflammatory disease, history of seizures/epilepsy, physical addiction to alcohol, medication or drugs (excluded: nicotine), insufficient compliance, present or past malignant tumour involving the central nervous system, severe psychiatric disease, clinically manifest bilateral hemiparesis or infarcts in the primary motor cortex or along the corticospinal tract in the hemisphere ipsilateral to the hemiparesis, pre\-existing cerebral infarctions with hemiparesis or pre\-existing cerebral infarctions in the primary motor cortex or along the corticospinal tract, excluding microvascular changes (eg, clinically asymptomatic lacunae \<1 cm), known brain lesion (surgical, traumatic), evidence for enhanced cerebral pressure, severe cardiac dysfunction, life expectancy \<12 months, National Institutes of Health Stroke Scale Score (NIHSS) \>20, blood glucose imbalances resistant to treatment (\<50 mg/dL or \>300 mg/dL), elevated blood pressure resistant to treatment (\>185/110 mm Hg), systemic thrombolysis using alteplase or thrombectomy
•within the last 24 hours before enrolment in study, medication with benzodiazepines, high\-potency antipsychotics or tricyclic antidepressants before hospitalisation or long\-term during hospitalisation.